Evidence map›Paper›PMID 26190981›Full record

ArticleFrontiers in behavioral neuroscience2015

Targeted genetic manipulations of neuronal subtypes using promoter-specific combinatorial AAVs in wild-type animals.

Heinrich S Gompf, Evgeny A Budygin, Patrick M Fuller, Caroline E Bass

Open access · goldAbstract read
In one paragraph

Article in Frontiers in behavioral neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Gene therapy for neurotransmitter-related disorders.Journal of inherited metabolic disease · 2024
    Review
  8. Article
  9. Article
  10. AAV-iScience · 2023
    Article
  11. Article
  12. Modulation of deep neural circuits with sonogenetics.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Article
  14. A noradrenergic-hypothalamic neural substrate for stress-induced sleep disturbances.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Heinrich S GompfDepartment of Neurology, Division of Sleep Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center Boston, MA, USA.
Evgeny A BudyginDepartment of Neurobiology and Anatomy, Wake Forest School of Medicine Winston Salem, NC, USA ; Department of Biology, St. Petersburg State University St. Petersburg, Russia.
Patrick M FullerDepartment of Neurology, Division of Sleep Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center Boston, MA, USA.
Caroline E BassDepartment of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo Buffalo, NY, USA.
Beth Israel Deaconess Medical Center · USHarvard University · USSt Petersburg University · RUUniversity at Buffalo, State University of New York · US

Funding

Molecular-Genetic Dissection of Subcortical Circuitry Regulating ArousalR01NS073613 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Patrick M Fuller · 2011 to 2026
$5.5M
Real-Time Accumbal Dopamine Signaling and Ethanol Drinking BehaviorR01AA022449 · NIAAA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BUDYGIN, EVGENY ALEXANDER · 2014 to 2018
$1.8M
CB1 and DA Receptor Deletion by RNAi in Cocaine Self-AdministrationK01DA024763 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BASS, CAROLINE EVELYN · 2008 to 2011
$568k
NIAAA NIH HHS R01 AA022449NIDA NIH HHS K01 DA024763NINDS NIH HHS R01 NS073613
6 · The paper itself

Abstract

Techniques to genetically manipulate the activity of defined neuronal subpopulations have been useful in elucidating function, however applicability to translational research beyond transgenic mice is limited. Subtype targeted transgene expression can be achieved using specific promoters, but often currently available promoters are either too large to package into many vectors, in particular adeno-associated virus (AAV), or do not drive expression at levels sufficient to alter behavior. To permit neuron subtype specific gene expression in wildtype animals, we developed a combinatorial AAV targeting system that drives, in combination, subtype specific Cre-recombinase expression with a strong but non-specific Cre-conditional transgene. Using this system we demonstrate that the tyrosine hydroxylase promoter (TH-Cre-AAV) restricted expression of channelrhodopsin-2 (EF1α-DIO-ChR2-EYFP-AAV) to the rat ventral tegmental area (VTA), or an activating DREADD (hSyn-DIO-hM3Dq-mCherry-AAV) to  the  rat  locus  coeruleus  (LC). High expression levels were achieved in both regions. Immunohistochemistry (IHC) showed the majority of ChR2+ neurons (>93%) colocalized with TH in the VTA, and optical stimulation evoked striatal dopamine release. Activation of TH neurons in the LC produced sustained EEG and behavioral arousal. TH-specific hM3Dq expression in the LC was further compared with: (1) a Cre construct driven by a strong but non-specific promoter (non-targeting); and (2) a retrogradely-transported WGA-Cre delivery mechanism (targeting a specific projection). IHC revealed that the area of c-fos activation after CNO treatment in the LC and peri-LC neurons appeared proportional to the resulting increase in wakefulness (non-targeted > targeted > ACC to LC projection restricted). Our dual AAV targeting system effectively overcomes the large size and weak activity barrier prevalent with many subtype specific promoters by functionally separating subtype specificity from promoter strength.

Indexed as

chemogeneticDREADDdual AAV targetinglocus coeruleus (LC)optogenetictyrosine hydroxylase (TH)ventral tegmental area (VTA)wild-type

Identifiers

PMID26190981
PMCPMC4488755
OpenAlexW1569867067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.